Racura Oncology Ltd · ASX:RAC
Racura Oncology — Race Oncology — Technical Presentation (September 2025)
27 slides from Racura Oncology's technical presentation, September 2025
Slide 1: At the Heart of Cancer Care
S e p t e m b e r 2 0 2 5 A T T H E H E A R T O F C A N C E R C A R E AT THE HEART OF CANCER CARE Dr Daniel Tillett – CEO Prof Michael Kelso – VP of Research Dr Pete Smith – Exec Chair Isomer IP Webinar 0 ASX: RAC | RACE ONCOLOGY LIMITED | ABN 61 149 318 749 11
Slide 2: Overview
Overview A T T H E • Bisantrene found to consist of three photoisomers with H E A R T different biological and anticancer activities, which rapidly O F interconvert upon exposure to visible light. C A N C E R • Race has created a range of manufacturing and physical processes to only infuse the pure
Slide 3: Chemistry & Discovery
333 A T T H E H E A R T O F C A N C E R C A R E Chemistry & Discovery
Slide 4: Bisantrene – Chemical Structure
4 A T T H E H E A R T O F C A N C E R C A R E Bisantrene – Chemical Structure
Slide 5: Bisantrene – Possible Isomers
5 A T T H E H E A R T O F C A N C E R C A R E Bisantrene – Possible Isomers
Slide 6: Bisantrene Isomerism – First observations
Bisantrene Isomerism – First observations A T T H E H E A R T • Results from a toxicology study in animals - Measured bisantrene in the blood by liquid chromatography/mass spectrometry (LCMS) O F C A N C E R C A R E Bisantrene = 1 peak Variable appearance of a second peak with (expected) same molecu
Slide 7: Detective Work (Race Team)
Detective Work (Race Team) A T T H E • Dissolve pure (E,E)-bisantrene in water, expose it to light and monitor by HPLC H E A R T O F C A N C E R (E,E)-bisantrene C A R E (E,E)-bisantrene ?? (E,E)-bisantrene ?? increasing • Observation: Visible ambient light triggers rapid formation of the ?? second
Slide 8: Detective Work – What is the Second Peak?
Detective Work – What is the Second Peak? A T T H E • To identify the second peak need to isolate a pure sample H E A R T O F C A N C E R Pure second peak!! C A R E (E,E)-bisantrene peak reappears RAPID 8
Slide 9: Detective Work – Voila! It's (E,Z)-bisantrene
Detective Work – Voila! It’s (E,Z)-bisantrene A T T H E H E A R T H Nuclear Magnetic Resonance (NMR) analysis 1 O F unambiguously proved the second peak is (E,Z)- C A N C E R bisantrene C A R E 9
Slide 10: Bisantrene – Photoisomerism
10 A T T H E H E A R T O F C A N C E R C A R E Bisantrene – Photoisomerism
Slide 11: (E,Z)-Bisantrene has low anticancer activity
(E,Z)-Bisantrene has low anticancer activity A T T H E Cytotoxicity Testing H E A R T • Expose pure (E,E)-bisantrene solution to light for different amounts of time to make different isomer mixtures O F C A N C E R • Test the different isomer mixtures for ability to kill MDA-MB-231 breast cancer cel
Slide 12: (E,Z)-bisantrene has low anticancer activity
(E,Z)-bisantrene has low anticancer activity A T T H E H E A R T • Measure how well an (E,E), (E,Z)-bisantrene mixture kills 143 individual cancer cell lines from 23 different tissue types compared O F to pure (E,E)-bisantrene C A N C E R C A R E (E,E)-bisantrene: 100% (E,E), 0% (E,Z) (E,E), (E,Z)-b
Slide 13: Patents & Value
A T T H E H E A R T O F Patents & Value C A N C E R C A R E Chemistry & Discovery 13 13
Slide 14: Composition of Matter IP
Composition of Matter IP A T T H E H E A R T • Composition of matter patent claims protect the O F chemical structure of the active drug C A N C E R • Strongest IP possible in the pharmaceutical industry C A R E • Composition of Matter IP drives significant value uplift for any drug. Why? • No gener
Slide 15: What is Required for a Patent?
What is Required for a Patent? A T T H E H E A R T Novelty Non-Obviousness Utility O F C A N C E R ü ü ü C A R E Bisantrene photoisomerism Only discovered through careful Only (E,E)-isomer active not previously reported scientific observations and follow-up R&D Race Oncology has filed three isomer p
Slide 16: Isomer Mixture Drugs
Isomer Mixture Drugs A T T H E H E A R T • European Medicines Agency (EMA) no longer approving drugs consisting of isomer mixtures – O F C A N C E R none since 2016 • FDA demands you provide strong evidence for why C A R E your API is not a single isomer • Why single-isomer drugs are better than mix
Slide 17: Plavix (Clopidogrel)
Plavix® (Clopidogrel) A T T H E H E A R T • Antithrombotic and antiplatelet drug O F C A N C E R • Original patent (1983) was an isomers mixture Pharmacologically active isomer • Later patent (1988) only claimed (S)-isomer C A R E • Approved by FDA as a pure (S)-isomer (S)-Clopidogrel • Over its 198
Slide 18: Lexapro (Escitalopram)
Lexapro® (Escitalopram) A T T H E H E A R T • Used for the treatment of depression O F • Citalopram was approved in 1998 as isomer Potent Isomer C A N C E R mixture C A R E • (S)-isomer later found to be 100 times more potent than the (R)-isomer and patented (S)-Citalopram • (S)-Citalopram (Escitalo
Slide 19: Commercial significance
19 A T T H E H E A R T O F C A N C E R C A R E Commercial significance
Slide 20: RC220
RC220 A T T H E • From a partnering point of view, composition of matter H E A R T patent claims are very valuable O F • Ensure that no other formulation can enter the market even if C A N C E R clinical studies are conducted • Any other (E,E)-bisantrene containing formulation would infringe C A R E
Slide 21: RC110 in acute myeloid leukemia (r/rAML)
RC110 in acute myeloid leukemia (r/rAML) A T T H E H E A R T Composition of matter patent O F would provide strong IP protection C A N C E R Phase II trials of (E,E)- of the RC110 formulation bisantrene RC110 in r/r AML C A R E • RC110 as a mono agent: 40% overall response rate.1 • RC110 in combinat
Slide 22: Performance of Second Line Mono Agents in AML
Performance of Second Line Mono Agents in AML A T T H E H E A R T Ivosidenib (Tibsovo) O F Olutasidenib (Rezlidhia) RC110 offers the highest C A N C E R Enasidenib (Idhifa) prevalence weighted benefit as a mono agent therapy for C A R E Ziftomenib r/r AML patients Gilteritinib (Xsopata) RC110 could
Slide 23: Potential to Partner RC110
Potential to Partner RC110 A T T H E • RC110 has been very effective in recent studies in AML H E A R T • Bisantrene was not protected by strong intellectual property O F • Only orphan drug designation - 7 years of exclusivity C A N C E R • Once orphan protection period expired generic RC110 competi
Slide 24: Conclusion
Conclusion A T T H E • Bisantrene can exist in three isomeric forms - (E,E), (E,Z) and (Z,Z) H E A R T • Photoisomerisation not known prior to Race’s discovery O F • Only (E,E)-bisantrene (RCDS1) shown to have potent anticancer activity C A N C E R • Race is using pure (E,E)-bisantrene in its RC110
Slide 25: Questions
A T T H E H E A R T O F C A N C E R C A R E Questions Race Oncology 25 A T T H E H E A R T O F C A N C E R C A R E 25
Slide 26: Important Notice and Disclaimer
Important Notice and Disclaimer A T T H E The material in this presentation has been prepared by Race Oncology Limited (ACN 149 318 749) (Company). H E A R T THIS IS NOT A PROSPECTUS This presentation is not a prospectus, product disclosure statement or disclosure document for the purposes of the Co
Slide 27: Contact
A T T H E H E A R T O F C A N C E R C A R E Contact P E T E S M IT H Executive Chair JA N E L O W E Investor & Media Relations +61 2 8051 3043 +61 411 117 774 peter.smith@raceoncology.com jane.lowe@irdepartment.com.au www.raceoncology.com Authorised for release by the Board ASX: RAC | RACE ONCOLOGY
Race Oncology — Technical Presentation (September 2025) on 6ix